KCI등재
SCOPUS
SCIE
A Big Step Forward in the New KGCA Guidelines
저자
Han Sang-Uk (Department of Surgery, Ajou University School of Medicine, 206 Worldcup-ro, Yeongtong-gu, Suwon 16502, Korea) ; Sang-Yong Son (Department of Surgery, Ajou University School of Medicine, Suwon, Korea.)
발행기관
학술지명
Journal of gastric cancer(Journal of Korean Gastric Cancer Association)
권호사항
발행연도
2023
작성언어
English
등재정보
KCI등재,SCOPUS,SCIE
자료형태
학술저널
수록면
1-2(2쪽)
제공처
소장기관
What is learned rapidly becomes outdated. Experiences and things learned by reading research evidence may be selective or inappropriately implemented. In addition, research evidence is everchanging and, consequently, no practitioner can keep abreast of all updates. However, quality and efficiency must be ensured to treat patients encountered in clinical practice. This may be the main reason why so much time is spent developing and reading guidelines.
A clinical guideline is a systematically developed series of recommendations designed to assist decisions about appropriate health care in specific clinical circumstances. Guidelines should be based on evidence, but interpretation and implementation of that evidence require appreciation of its potential limitations [1, 2]. Although the Korean Gastric Cancer Association (KGCA) has developed and published the first and second editions of gastric cancer treatment guidelines since 2004, they were not widely used due to inconsistencies in medical reality. However, the third edition of the guidelines published in 2018, which provides a comprehensive description and statements for key questions (KQs), was rapidly and widely applied in practice after publication [3].
This issue of Journal of Gastric Cancer welcomes the publication of new Korean Practice Guidelines for Gastric Cancer [4]. This fourth edition of the guidelines was developed by specially assembled, multidisciplinary groups of experts including surgeons, gastroenterologists, oncologists, radiologists, and pathologists, assisted by the National Evidence-based Healthcare Collaborating Agency. The aim was to produce up-to-date, relevant, and practical recommendations using new scientific evidence that emerged after publication of the previous edition.
There are 4 key points to consider when reading the new guidelines. First, the methodology used to draw conclusions about KQs was changed from a literature review to a systematic review. The level of evidence was also redefined based on the Grading of Recommendations, Assessment, Development, and Evaluation system, which is a de facto standard for high-quality systematic reviews and an essential component of trustworthy guidelines [5]. Second, the results of numerous Korean clinical studies such as SENORITA, PEGASUS-D, and PRODIGY as well as KLASS01–05 were used for the meta-analyses in these guidelines. It is very meaningful that the results of our research were used as a scientific basis for many KQs because this means that not only were our efforts worthwhile, but also that our international status in the academic society has risen further. Third, the emerging trend of anticancer treatments, such as in neoadjuvant chemotherapy, intraperitoneal chemotherapy, and palliative first-line nivolumab/second-line ramucirumab/third-line chemotherapy, was reflected in the new guidelines as much as possible. Lastly, considering that the number of gastric cancer survivors is growing due to early detection and improvements in therapeutics, surveillance for recurrence or nutritional assessment has been newly suggested [6]. However, this was based on a nationwide survey of each institution, not a clinical trial. Therefore, much remains to be done with regard to this issue in the next version of the guidelines.
Gastric cancer remains one of the most common causes of cancer death in Korea and worldwide. A wide spectrum of treatment modalities has been developed and applied to treat gastric cancer over the past decades: surgery, endoscopic treatment, systemic chemotherapy, immunotherapy, targeted therapy, and radiotherapy all have proven efficacy in gastric adenocarcinoma. Therefore, a multidisciplinary approach is now paramount for treatment selection. In this respect, it is encouraging that a multidisciplinary team worked together to generate the new guidelines. It is also heartening that the KGCA played a valuable role for its members with the publication of the new guidelines and has...
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)